Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Ketotifen on an Experimental Model of IgA Nephropathy

IgA 신증의 실험모델에서 케토티펜의 효과

  • Do, Young-Sun (Department of Pediatrics and Adolescent Medicine, Wonju Christian Hospital Yonsei University Wonju College of Medicine) ;
  • Soon, Eu-Jene (Department of Pediatrics and Adolescent Medicine, Wonju Christian Hospital Yonsei University Wonju College of Medicine) ;
  • NamGoong, Mee-Kyung (Department of Pediatrics and Adolescent Medicine, Wonju Christian Hospital Yonsei University Wonju College of Medicine)
  • 도영선 (연세대학교 원주의과대학 소아청소년과학교실) ;
  • 순유진 (연세대학교 원주의과대학 소아청소년과학교실) ;
  • 남궁미경 (연세대학교 원주의과대학 소아청소년과학교실)
  • Published : 2009.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The intestinal mucosal defect has been known as one of the pathogenicmechanisms of IgA nephropathy. Oral antigens usually induce the activation of Th2 cells and mast cells. These cells secrete cytokines IL-4, IL-5 and TGF-$\beta$, which increase IgA production. Although ketotifen (benzocycloheptathiophene) is an H1 antagonist and a mast cell membrane stabilizer, it could protect the gastrointestinal membrane through inhibiting the production of IL-4, IL-5, PGE2, and LTB4, and decreasing the activity of nitric oxide synthease. Therefore, we have investigated if ketotifen may protect the development of IgA nephropathy with an oral antigen. Methods : ICR mice were used as an animal model orally with Poliovax only [ketotifen (-)], the other group was given oral ketotifen [ketotifen (+)] in addition to Poliovax. Results : Mesangial IgA deposition developed in 11 out of the 18 mice in the ketotifen (-) group, while in three out of the nine mice in ketotifen (+) group. The mesangial change developed in 16 out of the 18 mice in the ketotifen (-) group, while in five out of the nine mice in the ketotifen (+) group. Serum IL-4 and IL-5 levels were not significantly lower in the latter group than in the former. Conclusion : According to the statistical results from the above, ketotifen therapy would be beneficial to reducing mesangial changes in IgA nephropathy.

목적 : 장점막 손상은 IgA 신증의 병리기전중의 하나로 알려져 있다. 구강항원은 보통 Th2 세포와 비반세포를 활성화 시킨다. 이러한 세포들은 IL-4, IL-5 TGF-${\beta}$와 같은 싸이토카인들을 분비하여 IgA 생성을 증가시킨다. 케토티펜(benzpxycloheptathiophene)은 H1항체이자 비반세포의 막안정제로 IL-4, IL-5, PGE2, LTB4 등의 생산을 억제하고, 질산화산소합성제의 활성화를 감소시켜 위장관막을 보호한다. 저자들은 구강항원으로 인한 IgA 신증의 발병을 케토티펜이 예방할 수 있는지 관찰하였다. 방법 : ICR 생쥐를 이용하여 구강 폴리오백신(백신군)을 투여하면서, 다른 군에서는 케토티펜(케토티펜군)을 백신과 동시에 투여하였다. 결과 : 메산지움의 IgA 침착은 백신군에서 18마리중 11마리에서 발생하였으나, 케토티펜군에서는 9마리 중 3마리에서 볼 수 있었다. 메산지움의 조직 변화는 백신군에서 18마리 중 16마리, 케토티펜 군에서는 9마리 중 5마리에서 볼 수 있었다. 혈청 IL-4, IL-5치는 케토티펜 군에서 백신군과 비교해 다소 낮기는 하지만 의미있는 감소는 하지 않았다. 결론 : 케토티펜은 IgA 신증의 사구체 변화를 감소시키는데 유효한 것으로 사료된다.

Keywords

References

  1. Fox CC, Lazenby AJ, Moore WC, Yardley JH, Bayless TM, Lichtenstein LM Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990:99:119-24.
  2. Konno S, Asano K, Okamoto K, Adachi M. Inhibition of cytokine production from humanperipheral blood leukocytes by anti-allergic agents in vitro. Eur J Pharmacol 264:265-8. https://doi.org/10.1016/0014-2999(94)00476-5
  3. Eliakim R, Karmeli F, Okon E, Rachmilewitz D. Ketotifen effectively prevents mucosaldamage in experimental colitis. Gut 1992:33:1498-503. https://doi.org/10.1136/gut.33.11.1498
  4. Karmeli F, Eliakim R, Okon E, Rachmilewitz D. Gastric mucosal damage is mediated bysubstance P and prevented by ketotifen. Gastroenterology 1991:100:1206-16.
  5. Eliakim R, Karmeli F, Rachmilewitz D. Ketotifen-old drug, new indication: Reduction ofgastric mucosal injury. Scand J Gastroenterol 1993:28:202-4. https://doi.org/10.3109/00365529309096072
  6. Sato M, Haizuka H, Asakura H. Relationship between serum IgA levels and CD4 subsets inIgA nephropathy. Nephron 1994:68:20-4. https://doi.org/10.1159/000188218
  7. Libetta C, Rampino T, Palumbo G, Esposito C, Dal-Canton A. Circulating serum lectins of patients with IgA nephropathy stimulate IL-6 release from mesangial cells. J Am Soc Nephrol 1997:8:208-13.
  8. Taniguchi Y, Yorioka N, Oda H, Yamakido M. Platelet-derived growth factor, IL-1 beta,IL-6R and tumor necrosis factor-alpha in IgA nephropathy. An immunohistochemicalstudy. Nephron 1996:74:652-60. https://doi.org/10.1159/000189470
  9. Parera M, Rivera F, Egido J, Campos A. The role of IL2 and serum-soluble IL-2 receptorcells in idiopathic IgA nephropathy. Clin Immunol Immunopathol 1992:63:196-9. https://doi.org/10.1016/0090-1229(92)90013-E
  10. Ashizawa M, Miyazaki M, Abe K, Furusu A, Isomoto H, Harada T, Ozono Y, Sakai H, Koji T, Kohno S. Detection of nuclear factor-kappa B in IgA nephropathy using Southwestern histochemistry. Am J Kidney Dis 2003:42:76-86. https://doi.org/10.1016/S0272-6386(03)00411-6
  11. Furusu A, Miyasaki M, Koji T, Abe Km Oaono Y, Harada T, Nakane PK, Hara K, Kohno S. Involvement of IL4 in human glomerulonephritis: an in situ hybridization study of IL4 mRNA and IL-4 receptor mRNA. J Am Soc Nephrol 1997:8:730-41.
  12. Montinaro V, Hevey K, A ventaggiato L, Fadden K, Esparza A, Chen A, et al. Extrarenal cytokines modulate the glomerular response to IgA immune complexes. Kidney Int 1992:42:341-53. https://doi.org/10.1038/ki.1992.295
  13. Chintalacharuvu SR, Emancipator SN. The glycosylation of IgA produced by murine B cellsis altered by Th2 cytokines. J Immunol 1997:159:2327-33.
  14. Chintalacharuvu SR, Nagy NU, Sigmund N, Nedrud JG, Amm ME, Emancipator SN. T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation. Clin Exp Immunol 2001:126:326-33. https://doi.org/10.1046/j.1365-2249.2001.01678.x
  15. Narendranathan M, Chitra P, KurienM, Philip J. Ketotifen in prevention of indomethacin-induced gastropathy. Indian J Gastoenterol 1999:18:76-7.
  16. Jones NL, Roifman CM, Griffiths AM, Sherman P. Ketotifen therapy for acute ulcerative colitis in children: a pilot study. Dig Dis Sci 1998:43:609-15. https://doi.org/10.1023/A:1018827527826
  17. Sakamoto-Ihara T, Suzuki Y, Kurusu A, Yamashita M, Horikoshi S, Tomino Y. Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy. Inflamm Res 2007;56:421-7. https://doi.org/10.1007/s00011-007-6145-z
  18. Ravinal RC, Costa RS, Coimbra TM, Dantas M, dos Reis MA. Mast cells, TGF-betal and myofibroblasts expression in lupus nephritis outcome. Lupus. 2005;14:814-21. https://doi.org/10.1191/0961203305lu2188oa
  19. Heyman SN, Karmeli F, Brezis M, Rachmilewitz D. The effect of ketotifen on nitric oxidesynthase activity. Br J Pharmacol 1997:120:1545-51. https://doi.org/10.1038/sj.bjp.0701063
  20. Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M. Nitric oxide and prostanoids protectthe renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 94:1069-75. https://doi.org/10.1172/JCI117421
  21. Kovcs T, Kun L, Schmelczer M, Wagner L, Davin JC, Nagy J. Do intestinal hyperpermeability and the related food antigens play a role in the progression of IgA nephropathy? I. Study of intestinal permeability. Am J Nephrol 1996:16:500-5. https://doi.org/10.1159/000169050
  22. Bazzi C, Sinico RA, Petrini C, Rizza V, Torpia R, Arrigo G, Ragni A, D'Amico G. Low dosesof drugs able to alter intestinal mucosal permeability to food antigens (5-aminosalicylic acid and sodium cromoglycate) do not reduce proteinuria in patientswith IgA nephropathy: a preliminary noncontrolled trial. Nephron 1992:61:192-5. https://doi.org/10.1159/000186870
  23. Sato M, Nakajima Y, Koshikawa S. Effect of sodium cromoglycate on an experimentalmodel of IgA nephropahty. Clin Neph 1987:27:141-6. https://doi.org/10.1159/000116211
  24. Jin SY, Choi IJ. The effect of sodium cromoglycate on the induction of experimental IgA nephropathy. Yonsei Med J 1990:31:33-48.
  25. Sato M, Takayama K, Kojima H, Koshikawa S. Sodium cromoglycate therapy in IgA nephropathy: a preliminary short-term trial. Am J Kidney Dis 1990:15:141-6.
  26. Yasuhiko T. IgA nephropathy: lessons from an animal model, the ddY mouse. J Nephrol 2008:21:463-7.
  27. Kivity S, Agami O, Topilsky M, Fireman E. Effect of nedocromil sodium and cromolinesodium on atopic basophil function. Int J Immunopharmacol 1996:18:75-8. https://doi.org/10.1016/0192-0561(95)00110-7
  28. Yan D, Zhou HR, Brooks KH, Pestka JJ Potential role for IL-5 and IL-6 in enhanced IgA secretion by Peyer's patch cells isolated from mice acutely exposed to vomitoxin. Toxicology 1997:122:145-58. https://doi.org/10.1016/S0300-483X(97)00087-5
  29. Xu-Amano J, Kiyono H, Jackson RJ, Staats HF, Fujihashi K, Burrows PD, Elson CO, Pillai S, McGhee JR. Helper T cell subsets for immunoglobulin A response: oralimmunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2cells in mucosa associated tissues. J Exp Med 1993:178:1309-20. https://doi.org/10.1084/jem.178.4.1309
  30. H hara, M Kurita, H Morioka, T Kuwabara, K Kuroda, M Matsuhashi, N Ishii, K Miura, M Shirai. Drug induced cystitis due to ketotifen fumarate-a case report. Nippon Hinyokika GaKKai Zasshi 1992:83:1906-9.
  31. Cook HT, Singh SJ, Wembridge DE, Smith J, Tam FW, Pusey CD. Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. Kidney Int 1999:55:1319-26. https://doi.org/10.1046/j.1523-1755.1999.00354.x